20+ genes found in
for solid tumor genetic testing
115+ genes included in
800+ clinical trials
15+ genes associated with
30+ targeted therapies
that are approved by the FDA
Copy number variations queried
AKT2, ALK, AR, AXL, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PPARG, PRKACA, PRKACB, PTEN, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSPO2, RSPO3, TERT
We are dedicated to helping every patient
access advanced genetic testing
Sema4 is contracted with all major national payors. For patients who are uninsured or underinsured, affordable payment plans, self-pay pricing, and other financial assistance options are also available.
Oncomine is a trademark of Thermo Fisher Scientific Inc. All rights reserved. No clinical claims, sponsorship, endorsement, or affiliation by Thermo Fisher Scientific is implied herein. The data generated by Sema4 is the sole responsibility of Sema4. The Oncomine Comprehensive Tumor Profiling Assay was developed by leading cancer institutes and regulatory agencies, and distributed by Thermo Fisher to support the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial. To learn more, please see Lih CJ, Harrington RD, Sims DJ, et al. Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial Molecular Analysis for Therapy Choice Clinical Trial. J Mol Diagn. 2017; 19: 313-327.